The Cardiorenal Axis From risk stratification to personalized treatment - 17.-18. January 2019 - Olink
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
The Cardiorenal Axis From risk stratification to personalized treatment 17.-18. January 2019 Getting to the heart of the matter – targeted protein biomarker discovery in cardiology January 16, 2019
Sehr geehrte Frau Kollegin, Dear Colleagues,
sehr geehrter Herr Kollege,
die klinische Medizin steht vor einschneidenden Umwälzungen. Clinical medicine is facing major upheavals. Not only in the tre-
Nicht nur in die Behandlung von Tumorleiden, sondern auch atment of tumor diseases, but also of chronic diseases and
von chronischen Erkrankungen und Stoffwechselstörungen metabolic disorders expensive biological drugs are more and
halten kostspielige biologische Medikamente mehr und mehr more incorporated. Drug target structures and indications be-
Einzug. Die Zielstrukturen und Indikationen werden spezifischer, come more specific, traditional nosological entities are resol-
tradierte nosologische Entitäten werden aufgelöst zugunsten ved in favor of molecular and genetically determined disease
molekular und genetisch determinierter Krankheitsdefinitionen. entities. Artificial intelligence is expected to assist doctors in
Künstliche Intelligenz soll künftig Ärzte in der Diagnostik und diagnosis and therapy in the future.
Therapie unterstützen.
The economic constraints, which are also subject to developed
Die wirtschaftlichen Restriktionen, denen auch hoch entwickel- health systems, turn it unavoidable that treatment strategies
te Gesundheitssysteme unterliegen, machen die Präzisierung become more precise. As it has been the case since then, ge-
von Behandlungsstrategien notwendig. Damit gilt wie seither, netic and biochemical diagnostics are the indispensable basis
dass genetische und biochemische Diagnostik die unabding- for rational therapeutic decisions. Hardly any modern, expensi-
bare Grundlage für rationale Therapieentscheidungen darstellt. ve therapy can be economically justified without the molecular
Kaum eine moderne, teure Therapie lässt sich mehr ohne das understanding of the underlying disease mechanisms.
molekulare Verständnis der zugrundeliegenden Erkrankungs-
With the current Symposium „The Cardiorenal Axis: From Risk
mechanismen wirtschaftlich rechtfertigen.
Stratification to Personalized Treatment“, we wish to analyze
Mit dem Symposium „Die kardiorenale Achse: Von der Risi- the relevance of these developments for heart and kidney di-
kostratifizierung zur personalisierten Behandlung“ wollen wir seases comprehensively and in an interdisciplinary fashion and
die Relevanz dieser Entwicklungen für Erkrankungen der Her- identify perspectives for improved patient care in the future.
zens und der Niere interdisziplinär und umfassend analysieren The range of topics therefore extends from genetics to new,
und Perspektiven für eine verbesserte Patientenversorgung prognostically relevant biomarkers, omics technologies and the
in der Zukunft aufzeigen. Das Themenspektrum reicht daher use of artificial intelligence in medicine.
von der Genetik über neue, prognostisch relevante Biomarker,
As in 2018, on Wednesday, January 16, 2019, in cooperation
Omics-Technologien und den Einsatz künstlicher Intelligenz in
with and with the support of Olink Proteomics, Uppsala, Swe-
der Medizin.
den, we will be offering a satellite symposium on the use of
Wie bereits im Jahr 2018 bieten wir in Zusammenarbeit und mit the Proximity Extension Assay (PEA) in biomarker research. The
Unterstützung der Firma Olink Proteomics, Uppsala, Schwe- number of participants of this event is limited. We therefore ask
den, am Mittwoch, den 16. Januar 2019, ein Satellitensympo- for early registration.
sium zum Thema Einsatz des Proximity Extension Assay (PEA) in
der Biomarker-Forschung an. Die Teilnehmerzahl dieser Veran- We hope to stimulate your interest with this program and would
staltung ist begrenzt. Wir bitten daher um frühzeitige Anmeldung. be pleased to welcome you in Mannheim.
Wir hoffen, mit diesem Programm Ihr Interesse zu wecken und Prof. Dr. med. Bernhard K. Krämer
würden uns über viele Teilnehmer und gute Diskussionen freuen. Univ. Prof. Dr. med. Winfried März
Prof. Dr. med. Christoph Wanner
Prof. Dr. med. Bernhard K. Krämer
Univ. Prof. Dr. med. Winfried März
Prof. Dr. med. Christoph Wanner
Die Veranstaltung wurde bei der Landesärztekammer Bayern This event was submitted to the Medical Association
zur Zertifizierung angemeldet. for CME certification.Program
Wednesday, January 16, 2019
Getting to the heart of the matter - targeted protein
biomarker discovery for the advancement of precision
medicine in cardiology and nephrology
11:15 Arrival, registration, coffee Biomarker discovery in cardiovascular disorders
Chair: W. Koenig, Munich, W. März, Mannheim
11:45 Lunch
15:15 Screening for new biomarkers in patients
12:30 Opening and overview on the topics
with cardiovascular disease
of the meeting
L. Wallentin, Uppsala
A. Ballagi, Uppsala, W. Koenig, Munich
16:00 Biomarkers are guiding my therapies
Epidemiological studies to advance A. Mebazaa, Paris
precision medicine
Chair: W. Koenig, Munich, W. März, Mannheim 16:25 Comprehensive molecular profiling towards
diagnostic biomarkers of acute aortic
12:40 Towards precision medicine for heart dissection
failure patients A. von Eckardstein, Zürich
F. Zannad, Nancy
16:50 Inflammatory signatures and risk of peripheral
13:25 Temporal patterns of blood biomarkers in and cardiovascular autonomic neuropathies
patients with chronic heart failure C. Herder, Düsseldorf
I. Kardys, Rotterdam
17:15 Plenary discussion
13:50 Role of proteomics in cardiovascular risk Chair: W. Koenig, Munich, W. März, Mannheim
evaluation
18:05 Closing remarks
E. Stroes, Amsterdam
A. Ballagi, Uppsala, W. März, Mannheim
14:15 Systems medicine approaches in cardio-
18:15 End of the first meeting day
vascular disease - from omics to biomarkers
T. Zeller, Hamburg 19:00 Evening event: Get together –
Dorint Hotel
14:40 Coffee
For further information on the proximity extension
technique visit www.olink.comProgram
Thursday, January 17, 2019
09:00 Registration, coffee Workshop I: Omics technologies
Chair: S. Lorkowski, Jena
09:15 Welcome and introduction into the
topic of the meeting 15:00 Ceramides – the rising stars in risk prediction
B. K. Krämer, Mannheim, C. Wanner, Würzburg,
R. Laaksonen, Tampere
W. März, Mannheim and Graz
15:25 The potential of omics technoloigies in
09:30 Welcome address from the Mayor of unravelung the biology of HDL
the city of Ludwigshafen A. von Eckardstein, Zürich
Jutta Steinruck, Ludwigshafen
15:50 Fatty acid profiling: with momentum after all
Perspectives C. von Schacky, Munich
Chair: Peter Lansberg, Groningen
16:25 Genome wide associations and
09:45 The future of laboratory services metabolomics: Focus on homoarginine
M. Floreani, Munich M. Kleber, Mannheim
10:15 The impact of health economics on 16:50 Coffee Break
clinical decision making
T. Wierzbicki, London
10:45 Novel approaches to risk stratification from Workshop II: Bioinformatics, artificial intelligence
the acute setting to the general population Chair: M. Herrmann, Graz
A. Beshiri, San Francisco Bay
11:15 Coffee Break 15:00 Personalized statin treatment in type 2
diabetes mellitus and hemodialysis
Genetics B. Genser, Wien
Chair: H. Dieplinger, Innsbruck
15:25 Tackling epistasis
11:30 The genetics of lipoprotein (a): B. Müller-Myhsok, Munich
Anything new about it? 15:50 Unraveling novel genes for familial
H. Schunkert, Munich
hypercholesterolemia
12:00 SuPAR as a biomarker of the cardio-renal axis: A. Rimbert, Groningen
Lessons from the Emory Cardiovascular Biobank 16:25 Machine learning in medicine – opportunities
S. Hayek, Ann Arbor
and hurdles
12:30 Genome wide association study of sclerostin T. Sauter, Luxembourg
J. Tobias, Bristol
16:50 Coffee Break
13:00 Lunch Break
13:30 Poster
Chair: Brigitte Zyriax, Hamburg, B. Fellström,
Uppsala, N. Marx, AachenProgram
Thursday, January 17, 2019 Friday, January 18, 2019
Workshop III: Biomarkers in kidney disease Clinial topics I
Chair: M. Zeier, Heidelberg Chair: W. Koenig, München
17:00 Cathepsin S: Predictive for vascular events? 8:30 The future of CVD risk prediction
H. J. Anders, Munich L. Wallentin, Uppsala
17:25 Circulating uromodulin inhibits vascular 9:00 Mechanisms of vasuclar disease in CKD
calcification by interfering with J. Jankowski, Aachen
pro-inflammatory cytokine signalling
9:30 Triglycerides: marker or maker?
J. Scherberich, Munich
M. Merkel, Hamburg
18:50 The lung, the heart, and the kidney:
10:00 Coffee Break
What is the link?
R. Bals, Homburg
Clinial topics II
18:15 Emerging biomarkers of the cardiorenal axis
Chair: D. Fliser, Homburg
in the PANCAKE study
M. Karakas, Hamburg
10:15 From lipoproteins to lipidomics
18:40 End of the second day J. Chapman, Paris
20:00 Get together 10:45 PCSK9 update
U. Laufs, Leipzig
11:15 SuPAR: a druggable target in kidney disease
Workshop IV: Metabolism and Inflammation
J. Reiser, Chicago
Chair: A. Ritsch, Innsbruck
11:45 SGLT2 inhibition in heart and kidney disease
17:00 Inflammasome activation in vascular disease C. Wanner, Würzburg
T. Speer, Homburg
12:15 Poster awards
17:25 Should we fortify food with vitamin D? B. Fellström
S. Pilz, Graz
12:30 Wrap up
18:50 Dental health in chronic kidney disease – B. K. Krämer, Mannheim, C. Wanner, Würzburg,
Results from the GCKD study W. März, Mannheim and Graz
C. Sommerer, Heidelberg
12:45 Lunch and farewell
18:15 How to exploit the results of CANTOS in
practice?
A. Zirlik, Graz
18:40 End of the second day
20:00 Get togetherPoster Presentations
High sensitve cardiac Tropinin I in hemodialysis patients Non-oxidised PTH and clinical outcomes in patients with
Artunc F. et al., Tübingen coronary artery disease
Dschietzig T et al., Berlin and Bensheim
Bariatric surgery associated weight loss positively
affects clot lysis time Chylomicronemia due to homozygosity for a novel
Baldia P.H. et al., Aachen variant of GPI-anchored HDL-binding protein 1
Eirich Katharina et al., Würzburg
A new case of Tangier disease
Bobbert T. et al., Berlin Association between helicobacter pylori infection and
laboratory biomarkers of iron metabolism
A critical update on solarium use and risk for malignant Enko D. et al., Leoben
melanoma: meta-analysis and evidence-based syste-
matic review Evaluation of the analytical performance of a liquid-chro-
Burgard B. et al., Homburg matography high-resolution mass-spectrometry for the
quantification of hepcidin-25 in human serum
A sound microbiota in a sound body through Enko D. et al., Leoben
apolipoprotein A-I and HDL: from mouse models to
humans (OCTOPUS) FH-ALERT: Laboratory guided identification of patients
Chiesa Giulia et al., Milan with familial hypercholesterolemia
Fath F. et al., Mannheim
Effect of the MoKaRi diet on the Coropredict score
Dawczynski Christine et al., Jena Effects of PCKS9 inhibition on non-cholesterol sterols
in a real world cohort
Effect of the MoKaRi diet on the plasma lipidome Fauler G. et al., Graz
Dawczynski Christine et al., Jena
The aldosterone to renin rato in the clinical laboratory
Bile acids in patients with uncontrolled type 2 diabetes Fenyvesi T. et al., Weiden
mellitus – The effect of two days of oatmeal treatment
Delgado Graciela et al., Mannheim Prevalence and determinants of vitamin D deficieny
Fenyvesi T. et al., Weiden
Combined use of uromodulin and eGFR to estimate
cardiovascular risk Seeking diagnostic biomarkers for acute aortic
Delgado Graciela et al., Mannheim dissection
Gawinecka Joanna et al., Zürich
Markers of endothelial function in smokers and non-
smokers – The Ludwigshafen Risk and Cardiovascular Systems biology approches to risk prediction
Health Study Gergei Ingrid et al., Mannheim
Delgado Graciela et al., Mannheim
Genome wide association study of klotho
The health economics of PCSK9 inhibition Gergei Ingrid et al., Mannheim
Dressel A. et al., MannheimPoster Presentations
Prediction of cardiovascular mortality using the coronary Clinical characteristics of three cases with
angiogram Cerebrotendineous xanthomatosis
Gleissner C. et al., Heidelberg Kassner Uschi et al., Berlin
Implementation of the Coropredict algorithm in the Fatty acid risk score improves risk prediction in primary
laboratory environment and secondary prevention compared to established risk
Grammer Tanja et al., Mannheim prediction algorithms
Kleber M. et al., Mannheim
Sitosterolemia: A case report
Grammer Tanja et al., Mannheim Prevalence of familial hypercholesterolemia in the LURIC
Study estimated by the CARRENAL custom designed
Generalized lipodystrophy in a woman with diabetes microarray
mellitus and hypertriglyceridemia due to novel Kleber M. et al., Mannheim
heterozygous mutations in LMNA and AGPAT2
Grammer Tanja et al., Mannheim Geno-wide polgenic score for CVD risk in persons
undergoing coronary angiography
Galectin 3 – interaction with the renin-angiotensin Kleber M. et al., Mannheim
system
Grübler M. et al., Bern A clinical case of hypobetalipoproteinemia
Klose G. et al., Bremen
“Fass Dir ein Herz”: the Austrian registry for familial
hypercholesterolemia Mortality prediction in stable hemodialysis patients with
Dieplinger H. et al., Vienna YKL-40
Lorenz G. et al., Munich
Cholesterol depletion impairs the contractile machinery
in neonatal rat cardiomyocytes nutriCARD 2.0: The BMBF competence cluster for
Hissa Bárbara et al., Mannheim nutrition and cardiovascular health
Lorkowski S et al., Jena
Cellular cholesterol efflux as a risk marker of
atherosclerosis Long- and short-term association of low-grade systemic
Hunjadi Monika et al., Innsbruck inflammation with cardiovascular mortality
Malle E. et al., Graz
Prognostic role of suPAR in the AtheroGene study
Karakas M. et al., Hamburg Estimation of the glomerular filtration rate using SDMA
as an index of kidney function
Diagnostic role of suPAR in BACC Meinitzer A. et al., Graz
Karakas M. et al., Hamburg
Thyoid metabolism and low density lipoproteins
Prognostic role of suPAR in BACC Merke Anette et al., Bensheim
Karakas M. et al., HamburgPoster Presentations
LURIC - 20 years of follow-up Cascade Screening and Registry for High Cholesterol
Moissl Angela et al., Mannheim (CaRe-High): interim results
Schmidt Nina and Schatz Ulrike et al., Mannheim and Dresden
Telomer length an mortality in the LURIC study
Pusceddu Irene et al., Bozen Interleukin-1alpha (IL-1A) is a key driver of CKD-associa-
ted vascular diseases
Predictive value of soluble ST2 in adolescent and adult Schmit D. et al., Homburg
patients with complex congenital heart disease.
Raedle-Hurst Tanja et al., Homburg The von Willebrand factor Tyr2561 allele is a gain-of-
function variant and a risk factor for early myocardial
FH Screening in children and reverse cascade screening infarction
for FH in their parents: A population-based approach in Brehm Maria et al., Hamburg
Bavaria
Sanin Veronika et al., Bavaria Urinary Dickkopf-3 (DKK3) predicts acute kidney injury
and subsequent loss of kidney function in patients with
The haptoglobin genotype modifies the relationship cardiac surgery
between vitamin E and mortality Schunk S. et al., Homburg
Renner W. et al., Graz
Interference of biotin in in-vitro diagnostics – Analysis of
Apolipoprotein C3 predicts CVD outcomes in the HCS field safety notices published by the BfArM in Germany
study Siekmeier, R. et al., Mannheim
Scharnagl H. et al., Graz
Interference of fulvestrant in in-vitro diagnostics for
Determination of LDL apolipoprotein B without determination of estrogen – Analysis of field safety
ultracentrifugation notices published by the BfArM in German
Scharnagl H. et al., Graz Siekmeier, R. et al., Mannheim
Effects of PCSK9 inhibition on lipoprotein fractions and LDL cholesterol to apoliopoprotein B ratio and
and remnants cardiovascular mortality
Scharnagl H. et al., Graz Silbernagel G. et al., Graz
Comparison of contemporary commercial methods to Apolipoprotein C-III mediates alternative NLRP3
measure lipoprotein (a) inflammasome activation in human monocytes
Scharnagl H. et al., Graz
Speer T. et al., Homburg
Chylomicron remnants predict CVD outcomes in the Hypobetalipoproteinemia due to a novel mutation in
HCS study APOB
Scharnagl H. et al., Graz
Steinmetz A. et al., Nürnberg
Genetics of patients with clinical suspicion of familial FGF-23 and iron metabolism
hypercholesterinemia in a lipid outpatients unit Stöhr R et al., Aachen
Schatz Ulrike et al., DresdenPoster Presentations A systems biological approach towards the discovery of functional biomarkers of high density lipoproteins Yalcinkaya M. et al., Zürich Association of CNDP1 genotype with all-cause mortality Yard B et al., Mannheim Effect of pulse pressure and double product on cardiovascular and overall mortality in LURIC Yazdani B. et al., Mannheim Measurement of vitamin D metabolites by mass spectroscopy Zelzer Siglinde et al., Graz A common variant in the NLRP3 inflammasome locus LOGISTICS associates with mortality Zewinger S. et al., Homburg Dickkopf-3 in urine identifies patients with progressive chronic kidney disease Zewinger S. et al., Homburg Phenome-wide Mendelian randomization study mapping the influence of the plasma proteome on complex diseases Zheng J. et al., Bristol
Logistics
The Cardiorenal Axis ADDITIONAL POSTERS AND INFORMATION
From risk stratification to Do you wish to contribute a poster?
personalized treatment Do you need other information?
MEETING VENUE PLEASE CONTACT
Dorint Kongresshotel Mannheim Univ.-Prof. Dr. med. Winfried März
Friedrichsring 6 SYNLAB Akademie
68161 Mannheim SYNLAB Holding Deutschland GmbH
P5,7
MEETING TIMES 68161 Mannheim
Wednesday, January 16, 2019 Telefon +49 621 43179-432
12:30 – 18:00 Telefax +49 621 43179-433
E-Mail winfried.maerz@synlab.com
Thursday, January 17, 2019
9:00 – 18:35
Prof. Dr. med. Bernhard K. Krämer
Friday, January 18, 2019 Medizinische Klinik V
8:30 – 12:30 Universitätsmedizin Mannheim
Theodor-Kutzer-Ufer 1-3
ORGANIZERS 68167 Mannheim
D·A·CH-Gesellschaft Prävention von Telefon +49 621 383-5172
Herz-Kreislauf-Erkrankungen e. V. Telefax +49 621 383-3804
Friedensallee 25 E-Mail bernhard.kraemer@umm.de
c/o MasterMedia GmbH
22765 Hamburg Prof. Dr. med. Christoph Wanner
Universitätsklinikum Würzburg
Medizinische Klinik V Medizinische Klinik und Poliklinik I
Universitätsmedizin Mannheim Abteilung Nephrologie
Theodor-Kutzer-Ufer 1-3
Oberdürrbacher Straße 6
68167 Mannheim
97080 Würzburg
SYNLAB Akademie Telefon +49 931 201-39030
SYNLAB Holding Deutschland GmbH Telefax +49 621 201-639030
P5,7 E-Mail Wanner_C@ukw.de
68161 MannheimSPONSORS
Sponsors
The Cardiorenal Axis
From risk stratification to
personalized treatment
MAIN SPONSOR Boehringer Ingelheim Pharma
GmbH & Co. KG
AMGEN GmbH 4.000 Euro
16.000 Euro
Immundiagnostik AG
500 Euro
SPONSORS
Abbott GmbH & Co. KG Merck Chemicals GmbH
1.000 Euro 2.000 Euro
Aegerion Pharmaceuticals GmbH MSD Sharp & Dohme GmbH
500 Euro 1.000 Euro
Akcea Therapeutics Novartis Pharma GmbH
5.000 Euro 1.000 Euro
Alexion Pharma Germany GmbH numares AG
1.000 Euro 1.000 Euro
Axon Lab AG Ocupharm GmbH
1.500 Euro 1.000 Euro
Bayer Vital GmbH Olink Proteomics
1.500 Euro 10.000 Euro
dx
bestbion dx GmbH & Siemens Healthcare
smarter diagnostics
sphingotec GmbH Diagnostics GmbH
1.500 Euro 1.000 EuroRegistration
The Cardiorenal Axis PARTICIPATION SYMPOSIA
From risk stratification to I will participate with ___ person(s) on the following days
personalized treatment ___ person(s) on 16.01.2019
___ person(s) on 17.01.2019
Please issue your binding registration by 22.12.2018 ___ person(s) on 18.01.2019
latest to www.synlab.com/de/mensch/fortbildung,
by e-mail to manuela.hormuth@synlab.com or
PARTICIPATION EVENING EVENTS
winfried.maerz@synlab.com or
by fax to +49 (0) 621 43179-433. Olink – 16.01.2019 only possible upon participation
in the Olink satellite meeting
Get together – 17.01.2019
CONTACT
SYNLAB Akademie OVERNIGHT STAYS
SYNLAB Holding Deutschland GmbH
Number of nights ___
P5, 7
68161 Mannheim Arrival 16.01.2019
Telefon +49 (0) 621 43179-432 Arrival 17.01.2019
Telefax +49 (0) 621 43179-433
E-Mail manuela.hormuth@synlab.com
winfried.maerz@synlab.com Please provide information completely and clearly
__________________________________________________
__________________________________________________
Address
We kindly ask you for binding registration, as __________________________________________________
non-attendance will generate avoidable costs for Telephone and fax
the organizers. __________________________________________________
E-mail
__________________________________________________
Participant name(s)
__________________________________________________
Date, signature, and stampNotes
Der/Die Veranstalter sichern zu, dass die Fortbildungsmaßnahme produkt- und/oder
dienstleistungsneutral gestaltet wird. Wissenschaftliche Leitung und Referenten werden
mögliche Interessenskonflikte, die die Inhalte der Fortbildungsmaßnahme betreffen, in
ihren Beiträgen offen legen.
Hinweise zum Datenschutz
Die SYNLAB Holding Deutschland GmbH behandelt personenbezogene Daten im
Einklang mit den Regeln der Allgemeinen Datenschutz-Grundverordnung vom 25. Mai
2018. Sie finden die Datenschutzerklärung hier www.synlab.de/de/datenschutz/ . Die-
se Einladung erhalten Sie im Auftrag der SYNLAB Holding Deutschland GmbH vom
Schwarzeck Verlag GmbH, Einsteinring 24, 85609 Aschheim, der Ihre Anschrift aus
dem Adressverzeichnis der ONEKEY Datenbank IQVIA Commercial GmbH & Co. OHG,
Unterschweinstiege 2-14, 60549 Frankfurt bezieht. Wie auch bisher haben Sie die Mög-
lichkeit, der Zusendung von Einladungen zu Veranstaltungen der SYNLAB Akademie zu
widersprechen, entweder schriftlich an SYNLAB Akademie für ärztliche Fortbildungen,
p5, 7, 68161 Mannheim, Telefon: 0621 43179432, Fax: 0621 43179433 oder durch
elektronische Mitteilung an fortbildungen.akademie@synlab.com. Die SYNLAB Akade-
mie wird im Fall des Widerspruchs dafür Sorge tragen, dass Sie künftig keine weiteren
Einladungen erhalten werden. Als Geschäftsbereich der SYNLAB Holding Deutschland
GmbH speichert und verarbeitet die SYNLAB Akademie Ihre persönlichen Daten erst
ab demjenigen Zeitpunkt, an dem Sie sich für die Teilnahme zu einer Veranstaltung
anmelden. Speicherung und Verarbeitung Ihrer persönlichen Daten erfolgen dann nur
zum Zweck der Durchführung der jeweiligen Veranstaltung.2019p-47-Einladungsflyer-FBN_19_20_04 © SYNLAB Holding Deutschland GmbH · Keine Haftung für Irrtümer, Fehler und falsche Preisangaben. Änderungen bleiben vorbehalten. Alle Texte, Fotos und Inhalte unterliegen dem Urheberrecht. Keine Verwendung ohne ausdrück liche Erlaubnis des Rechteinhabers.
You can also read
